The 4th World Congress on Controversies in Neurology (CONy) Barcelona, Spain, Palau de Congressos de Catalunya, October 28-31, 2010
Webcasting - Selected Topics
Thursday, October 28, 2010   Plenary Session II FREE ACCESS JOURNALS ARE IMPORTANT AND USEFUL: PRO W. Theodore FREE ACCESS JOURNALS ARE IMPORTANT AND USEFUL: CON R. Castellani IS ALZHEIMER'S DISEASE A HOMOGENEOUS NOSOLOGIC ENTITY? YES P. Martinez Martin IS ALZHEIMER'S DISEASE A HOMOGENEOUS NOSOLOGIC ENTITY? NO A.D. Korczyn Friday, October 29, 2010 Hall A - Epilepsy   Session 1 Epilepsy: Less Conventional Treatments SHOULD HORMONAL THERAPY BE USED TO TREAT EPILEPSY? YES E. Ben-Menachem HORMONAL THERAPY SHOULD NOT BE USED TO TREAT EPILEPSY M. Sperling COMMENT M. Carreno Martinez SHOULD RECENTLY APPROVED ANTIEPILEPTIC DRUGS (AEDS) BE USED EARLY IN THE TREATMENT OF EPILEPSY? THE ANSWER IS YES D. Schmidt SHOULD RECENTLY APPROVED ANTIEPILEPTIC DRUGS (AEDS) BE USED EARLY IN THE TREATMENT OF EPILEPSY? NO E. Beghi COMMENTARY M. Sperling     Session 2 Epilepsy: Psychological Aspects   SHOULD PATIENTS WITH EPILEPSY WHO ARE DEPRESSED BE ROUTINLY TREATED WITH ANTIDEPRESSANT MEDICATION OR VAGUS NERVE STIMULATION? VNS E. Ben-Menachem SHOULD PATIENTS WITH EPILEPSY WHO ARE DEPRESSED BE ROUTINLY TREATED WITH ANTIDEPRESSANT MEDICATION OR VAGUS NERVE STIMULATION? ADM D. Schmidt COMMENTARY W. Theodore Saturday, October 30, 2010 Hall A - Multiple Sclerosis   Session 14: Etiology and Pathogenesis of MS DOES CHRONIC VENOUS INSUFFICIENCY PLAY A ROLE IN MS PATHOGENESIS? YES P. Zamboni DOES CHRONIC VENOUS INSUFFICIENCY PLAY A ROLE IN MS PATHOGENESIS? NO O. Stüve COMMENTARY A. Miller ARE INFECTIONS KEY ENVIRONMENTAL FACTORS IN MS? NO A. Chaudhuri   Session 16: New Players in MS SHOULD ALL MS PATIENTS BE TREATED WITH STATINS? YES O. Stüve SHOULD ALL MS PATIENTS BE TREATED WITH STATINS? NO R. Milo FUMARATE J. Losy BONE MARROW TRANSPLANTATION D. Karussis TERIFLUNOMIDE M. Freedman LAQUINIMOD P. Vermersch CLADRIBINE P. Rieckmann EMERGING TREATMENTS FOR PSEUDOBULBAR AFFECT D. Wynn   Saturday, October 30, 2010 Hall B - Headache / Pain   Session 19 Headache: What causes post traumatic headache - Will CRGP antagonists be effective? WILL THE FIRST MARKETED CGRP ANTAGONIST BE AN IMPORTANT ADDITION TO THE MIGRAINE TREATMENT ARMAMENTARIUM? YES A. Rapoport WILL THE FIRST MARKETED CGRP ANTAGONIST BE AN IMPORTANT ADDITION TO THE MIGRAINE TREATMENT ARMAMENTARIUM? NO M. Levin COMMENTARY N. Mathew   Session 28: Biomarkers in Diagnositcs of Neurological Disorders THE PLACE OF SURROGATE ENDPOINTS IN THE DEVELOPMENT OF NEW NEUROLOGICAL MEDICINES P. Feldschreiber